初治弥漫大B细胞淋巴瘤患者血清白细胞介素-6水平及其预后意义

doi:10.3760/cma.j.cn441417-20240924-07025

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (7): 1179-1183.DOI: 10.3760/cma.j.cn441417-20240924-07025

初治弥漫大B细胞淋巴瘤患者血清白细胞介素-6水平及其预后意义

张进萍¹ 陈玲²^，³ 黄震宇⁴ 王颖² 黄晓玲² 黄豪博²

¹福州市第二总医院输血科，福州 350007；²福建医科大学附属协和医院输血科，福州 350001；³福建医科大学医学技术与工程学院，福州 350122；⁴福建技术师范学院食品与生物工程学院，福州 350300

收稿日期:2024-09-24 出版日期:2025-04-01 发布日期:2025-04-18
通讯作者: 黄豪博，Email：huanghaobo1981@163.com
基金资助:
福建省科技创新联合资金项目（2019Y9050）；福建省财政厅卫生健康专项（2021XH007）；福建医科大学启航基金（2021QH1050）

Serum level of interleukin-6 and its prognostic significance in patients with newly diagnosed diffuse large B-cell lymphoma

Zhang Jinping¹, Chen Ling^2,3, Huang Zhenyu⁴, Wang Ying², Huang Xiaoling², Huang Haobo²

¹Department of Blood Transfusion, Fuzhou Second General Hospital, Fuzhou 350007, China; ²Department of Blood Transfusion, Fujian Medical University Union Hospital, Fuzhou 350001, China; ³School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China; ⁴School of Food and Bioengineering, Fujian Polytechnic Normal University, Fuzhou 350300, China

Received:2024-09-24 Online:2025-04-01 Published:2025-04-18
Contact: Huang Haobo, Email: huanghaobo1981@163.com
Supported by:
Joint Funds for the Innovation of Science and Technology, Fujian Province (2019Y9050); Special Financial Funds of Fujian Province (2021XH007); Startup Fund for Scientific Research of Fujian Medical University (2021QH1050)

摘要/Abstract

摘要：

目的　探讨初治弥漫大B细胞淋巴瘤（DLBCL）患者血清白细胞介素-6（IL-6）水平及其预后意义。方法　回顾性选取2017年10月至2021年12月初诊于福州市第二总医院和福建医科大学附属协和医院的初治DLBCL患者66例为病例组，选取福建医科大学附属协和医院同期健康体检志愿者35例为对照组。病例组男39例，女27例，中位年龄59岁；对照组男10例，女25例，中位年龄39岁。比较两组血清IL-6水平。66例初治DLBCL患者中4例失访，62例纳入进一步分析。采用受试者操作特征曲线获取血清IL-6水平预测患者预后的截断值，按截断值将患者分为高水平组（IL-6≥15.6 ng/L）39例和低水平组（IL-6<15.6 ng/L）23例。比较两组患者的临床和实验室特征及3年总生存期（OS）、无进展生存期（PFS）。采用χ²检验、t检验进行统计分析。结果　病例组患者的血清IL-6水平高于对照组［（35.95±33.66）ng/L比（1.66±0.77）ng/L］，差异有统计学意义（t=6.012，P<0.001）。血清IL-6水平预测DLBCL患者预后的最佳截断值为15.6 ng/L，曲线下面积为0.705，95%置信区间为0.558～0.852（P<0.05）。高水平组有B症状、美国国家综合癌症网络国际预后指数≥4分患者比例均高于低水平组［58.97%（23/39）比13.04%（3/23）、79.49%（31/39）比43.48%（10/23）］，3年OS率、PFS率均低于低水平组［71.79%（28/39）比100.00%（23/23）、56.41%（22/39）比82.61%（19/23）］，差异均有统计学意义（均P<0.05）。结论　初治DLBCL患者的血清IL-6水平异常升高，且血清IL-6高水平与患者不良预后有关。

关键词:

弥漫大B细胞淋巴瘤, 白细胞介素-6, 预后

Abstract:

Objective　To explore the serum level of interleukin-6 (IL-6) in patients with newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL) and its clinical significance. Methods　A total of 66 patients with ND-DLBCL who were admitted to Fuzhou Second General Hospital and Fujian Medical University Union Hospital and 35 cases of healthy control individuals from Oct 2017 to Dec 2021 were selected for the retrospective analysis. Among the patients with ND-DLBCL, there were 39 males and 27 females with a median age of 59 years old. Among the healthy control individuals, there were 10 males and 25 females with a median age of 39 years old. The serum IL-6 levels were compared between the two groups. Of the 66 ND-DLBCL patients, 4 were lost to follow-up and 62 were included for further analysis. The optimal cut-off value of serum IL-6 level to predict prognosis was obtained by the receiver operating characteristic curve. The patients were divided into a high level group (IL-6 ≥15.6 ng/L, 39 cases) and a low level group (IL-6 <15.6 ng/L, 23 cases) according to the cut-off value. The clinical and laboratory characteristics, 3-year overall survival (OS) and progression-free survival (PFS) of the two groups were compared. χ² test and t test were used for statistical analysis. Results　The serum level of IL-6 in the patients with ND-DLBCL [(35.95±33.66) ng/L] was higher than that in the healthy control individuals [(1.66±0.77) ng/L] (t=6.012, P<0.001). The optimal cut-off value of serum level of IL-6 for prognosis in patients with ND-DLBCL was 15.6 ng/L, and the area under curve was 0.705 (0.558-0.852) (P<0.05). Compared with the group with low level of serum IL-6, the proportions of the patients with presence of B symptoms [58.97% (23/39) vs. 13.04% (3/23)] and high National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) (≥4 points) [79.49% (31/39) vs. 43.48% (10/23)] were higher in the high level group, but the OS rate of 3-year [71.79% (28/39) vs. 100.00% (23/23)] and the PFS rate of 3-year [56.41% (22/39) vs. 82.61% (19/23)] were lower in the high level group (all P<0.05). Conclusions　There was an abnormal elevation of serum IL-6 level in patients with ND-DLBCL. Meanwhile, high level of serum IL-6 was associated with poor prognosis in patients with ND-DLBCL.

Key words:

Diffuse large B cell lymphoma, Interleukin-6, Prognosis

张进萍陈玲黄震宇王颖黄晓玲黄豪博.

初治弥漫大B细胞淋巴瘤患者血清白细胞介素-6水平及其预后意义 [J]. 国际医药卫生导报, 2025, 31(7): 1179-1183.

Zhang Jinping, Chen Ling, Huang Zhenyu, Wang Ying, Huang Xiaoling, Huang Haobo.

Serum level of interleukin-6 and its prognostic significance in patients with newly diagnosed diffuse large B-cell lymphoma [J]. International Medicine and Health Guidance News, 2025, 31(7): 1179-1183.

参考文献

[1] Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study[J]. Blood, 2017, 130(16):1800-1808. DOI: 10.1182/blood-2017-03-769620.
[2] Rose-John S, Jenkins BJ, Garbers C, et al. Targeting IL-6 trans-signalling: past, present and future prospects[J]. Nat Rev Immunol, 2023, 23(10):666-681. DOI: 10.1038/s41577-023-00856-y.
[3] Rose-John S. Blocking only the bad side of IL-6 in inflammation and cancer[J]. Cytokine, 2021, 148: 155690. DOI: 10.1016/j.cyto.2021.155690.
[4] Rose-John S. Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer[J]. FEBS Lett, 2022, 596(5):557-566. DOI: 10.1002/1873-3468.14220.
[5] Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma[J]. Leuk Lymphoma, 2012, 53(3):411-416. DOI: 10.3109/10428194.2011. 621566.
[6] Hashwah H, Bertram K, Stirm K, et al. The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma[J]. EMBO Mol Med, 2019, 11(10):e10576. DOI: 10.15252/emmm.201910576.
[7] Preti HA, Cabanillas F, Talpaz M, et al. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma[J]. Ann Intern Med, 1997, 127(3):186-194. DOI: 10.7326/0003-4819-127-3-199708010-00002.
[8] Al-Khatib SM, Abdo N, Al-Eitan LN, et al. The impact of IL-6 and IL-10 gene polymorphisms in diffuse large B-cell lymphoma risk and overall survival in an arab population: a case-control study[J]. Cancers (Basel), 2020, 12(2):382. DOI: 10.3390/cancers12020382.
[9] Talaat RM, Abdel-Aziz AM, El-Maadawy EA, et al. CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL)[J]. Immunol Invest, 2015, 44(3): 265-278. DOI: 10.3109/08820139.2014.989328.
[10] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5): 579-586. DOI: 10.1200/JCO.2006.09.2403.
[11] Liu H, Yan R, Xiao Z, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling[J]. Breast Cancer Res, 2023, 25(1):43. DOI: 10.1186/s13058-023-01642-3.
[12] Zhao C, Zeng N, Zhou X, et al. CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3[J]. BMC Cancer, 2023, 23(1):392. DOI: 10.1186/s13058-023- 01642-3.
[13] Hou Y, Zhao W, Yang Z, et al. Serum amyloid A (SAA) and Interleukin-6 (IL-6) as the potential biomarkers for gastric cancer[J]. Medicine (Baltimore), 2022, 101(43):e31514. DOI: 10.1097/MD.0000000000031514.
[14] Laurino S, Brancaccio M, Angrisano T, et al. Role of IL-6/STAT3 axis in resistance to cisplatin in gastric cancers[J]. Biomedicines, 2023, 11(3):694. DOI: 10.3390/biomedicines11030694.
[15] 周光婷,王刚. T淋巴细胞亚群、IL-6在胃癌患者中的表达及其与预后的相关性[J]. 国际医药卫生导报,2024,30(15):2585-2589. DOI:10.3760/cma.j.issn.1007-1245.2024. 15.024.
[16] Liang Q, Gong M, Zou JH, et al. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma[J]. Drug Resist Updat, 2023, 68: 100957. DOI: 10.1016/j.drup.2023. 100957.
[17] Krizanac M, Mass Sanchez PB, Schroder SK, et al. Lipid-independent regulation of PLIN5 via IL-6 through the JAK/STAT3 axis in Hep3B cells[J]. Int J Mol Sci, 2023, 24(8):7219. DOI: 10.3390/ijms24087219.
[18] Hu F, Song D, Yan Y, et al. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation[J]. Nat Commun, 2021, 12(1):3651. DOI: 10.1038/s41467-021-23923-1.
[19] Turano M, Cammarota F, Duraturo F, et al. A potential role of IL-6/IL-6R in the development and management of colon cancer[J]. Membranes (Basel), 2021, 11(5):312. DOI: 10.3390/membranes11050312.
[20] Pastrez PRA, Barbosa AM, Mariano VS, et al. Interleukin-8 and interleukin-6 are biomarkers of poor prognosis in esophageal squamous cell carcinoma[J]. Cancers (Basel) 2023, 15(7):1997. DOI: 10.3390/cancers15071997.
[21] Emilie D, Wijdenes J, Gisselbrecht C, et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms[J]. Blood, 1994, 84(8):2472-2479. DOI: 10.1016/0959-8049(94)90870-2.
[22] Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, et al. Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal[J]. J Hematol Oncol, 2023, 16(1):43. DOI: 10.1186/s13045-023-01440-6.
[23] Zhong W, Zhu Z, Xu X, et al. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels[J]. J Exp Clin Cancer Res, 2019, 38(1):73. DOI: 10.1186/s13046-019- 1081-7.
[24] Bao C, Gu J, Huang X, et al. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes[J]. Cytokine, 2023, 169:156289. DOI: 10.1016/j.cyto.2023.156289.
[25] Dlouhy I, Filella X, Rovira J, et al. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma[J]. Leuk Res, 2017, 59:20-25. DOI: 10.1016/j.leukres.2017.05.014.

初治弥漫大B细胞淋巴瘤患者血清白细胞介素-6水平及其预后意义

Serum level of interleukin-6 and its prognostic significance in patients with newly diagnosed diffuse large B-cell lymphoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	邵远王志斌阚炳华. 自动乳腺容积成像联合miR-22-3p、PDGF对乳腺癌患者淋巴结转移及预后的关系 [J]. 国际医药卫生导报, 2025, 31(8): 1244-1249.
[2]	李广洲王红雷贺洋胡翠陈艳浩. 扩大淋巴结清扫胰十二指肠切除手术治疗胰腺癌患者的效果 [J]. 国际医药卫生导报, 2025, 31(8): 1327-1331.
[3]	李勇平吴水淼焦亲任佳辉张潇. 血清Syndecan-1、Endocan-1、GRP78与老年重症肺炎并发ARDS患者病情及预后的关系 [J]. 国际医药卫生导报, 2025, 31(7): 1173-1178.
[4]	朱鹏唐文玲覃刚. 结直肠癌中微小RNA功能及临床价值进展 [J]. 国际医药卫生导报, 2025, 31(6): 886-890.
[5]	于明英李媛燕普. 3D和2D腹腔镜手术治疗胃肠道癌症患者的短期预后比较 [J]. 国际医药卫生导报, 2025, 31(6): 900-907.
[6]	潘文昕姜伟炜. 结肠镜检查时机对缺血性结肠炎患者预后影响的研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 914-917.
[7]	郭玉格刘维帅马平丽. 子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系 [J]. 国际医药卫生导报, 2025, 31(6): 954-959.
[8]	张雪锋吕艳艳戴璐. 血清JAK-STAT信号通路相关蛋白对类风湿性关节炎患者的预后评估 [J]. 国际医药卫生导报, 2025, 31(6): 960-964.
[9]	文斐岑瑞祥. 3-磷酸甘油醛脱氢酶在喉部鳞状细胞癌中的功能及临床意义 [J]. 国际医药卫生导报, 2025, 31(6): 965-972.
[10]	谢紫阳姜小建孙佳折彦儒. 原发性肺癌患者血清非编码长链RNA及微RNA表达水平与预后的关系 [J]. 国际医药卫生导报, 2025, 31(6): 983-989.
[11]	赵金鹏高呈飞吕晓东. 浸润性非小细胞肺癌患者水平裂分化情况及肿瘤边缘-水平裂距离与预后的关系 [J]. 国际医药卫生导报, 2025, 31(5): 761-765.
[12]	刘珍珍刘谩贾永庆杨美菊. miR-6884-5p在非小细胞肺癌中的表达及与肿瘤标志物的相关性 [J]. 国际医药卫生导报, 2025, 31(5): 766-770.
[13]	洪金全黄晓玲黄震宇黄豪博. 弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展 [J]. 国际医药卫生导报, 2025, 31(4): 559-562.
[14]	张英王娟陈锐蔡武全赵卓. 血清CRP、IL-6、IL-13、IgE对儿童复杂性急性阑尾炎的诊断价值 [J]. 国际医药卫生导报, 2025, 31(2): 231-235.
[15]	张君高伟吕金鹏仲莉梅. 血清miRNA生物标志物预测鼻咽癌患者临床预后的价值 [J]. 国际医药卫生导报, 2025, 31(2): 303-307.